Glucagon-like peptide-1 (GLP-1) receptor agonist treatment is associated with lower risk for incident chronic kidney disease (CKD) and death relative to treatment with a dipeptidyl peptidase-4 inhibitor or sulfonylurea. This study examined within class effects of GLP-1 receptor agonists on kidney outcomes in type 2 diabetes (T2D) and moderate cardiovascular risk.